Newsletter

www.PennyStockAlerts.com does its best to bring you accurate information but errors may and sometimes do occur. Always do your own research before trading. PennyStockAlerts.com is not a licensed financial advisor.  This is a paid marketing newsletter which will state compensation, if any, for the specific company being marketed in the disclaimer at the end of this message.  

My Ultimate Sector Combination Alert is PMCB - PharmaCyte Biotech

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box^®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known chemotherapy prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. PharmaCyte Biotech is also working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.

In addition, PharmaCyte Biotech is developing treatments for cancer based upon chemical constituents of the Cannabis plant, known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit the benefits of Cell-in-a-Box^® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides PharmaCyte Biotech the rare opportunity to develop “green” approaches to fighting deadly diseases, such as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.

Website:

www.pharmacytebiotech.com

www.pharmacytebiotech.com/media

Now we are going to be focusing on what may just be the hottest MJ Biotech OTC ticker of 2015. Yes, that’s a bold statement, but we say it for good reason… it operates in TWO of the hottest, most active sectors on the small markets: Biotech and MJ!

 

This Company and its technology are the “Real Deal”:

 

  - Total assets valued at $6.62 MILLION!

  - The Company’s technology was just featured on the Discovery Channel LAST WEEK!

  - It reached 96Mln households

  - Its research received a Schedule 1 License by the DEA

  - The FDA has granted the Company an Orphan Drug Designation

 

Impressed yet? This is not your typical report as this new alert is not your typical small market company.

 

MJ and Biotech are two of the hottest (if not THE two hottest) sectors on the small markets right now… and our new alert, PharmaCyte Biotech (PMCB), operates in both:

 

Put PMCB on the top of you Watch-list right away!

 

Biotech: PMCB is a clinical stage biotech company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box.

 

MJ: PharmaCyte Biotech is developing treatments for cancer based upon chemical constituents of the Cannabis plant, known as cannabinoids.

 

PMCB has very recently released groundbreaking news regarding its Cell-in-a-Box technology. In fact, the technology was featured in a segment on the Discovery Channel and ION Network, reaching more than 96Mln households.

 

You can watch the Discovery Channel segment here:

https://www.youtube.com/watch?v=pqorMR_yEZQ

 

Read about it here:

http://finance.yahoo.com/news/pharmacyte-biotech-releases-healthwatch-segment-123000446.html

Since the middle of last year, as you can see in the chart, PMCB provided many trade opportunities as it rose and fell consistently, many times over many months, from the .30 range to the .15 range.

 

Just recently it slipped a bit lower…and now as of the latest close, it signaled a reversal by forming a doji style candlestick...a trader's favorite signal to indicate a reversal. 

It's also just finally closed RIGHT above the support level that has never failed on the 6 month chart...the 10 cent range.

The 10 cent range was solid as a rock in March.

IF it stays that way, then we are setup at the best possible entry point to play a bounce!!

 
A swing back up from this level would mean huge percentages!

 

PMCB has also been called a better class of company, a “best of the best” on the small markets, if you will…so let’s get to it:

 

 


 

Analyst Report issued by BrokerBank Securities:

PharmaCyte Biotech Analyst Report

 

PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box”.

 

Although the Discovery Channel news is exciting for traders, for PMCB the recent real “big deal” news is this:

 

PharmaCyte Biotech Advances Cannabinoid Research With Schedule 1 License

 

According to the news, PMCB’s research partner, the University of Northern Colorado (UNC), “successfully obtained a Schedule 1 license from the U.S. Drug Enforcement Agency (DEA) enabling the company to continue development of tumor-targeted treatments for serious and deadly cancers by utilizing cannabinoid prodrugs in combination with Cell-in-a-Box live cell encapsulation.”

 

The news further explains:

 

“Although (MJ) is legal in the state of Colorado, use of Cannabis for research purposes at an institution that has federal grants such as UNC is not permitted by the DEA without a Schedule 1 license. The source for the plant material is regulated by DEA, and this material must be obtained through the National Institute for Drug Abuse. With the DEA license, it is now possible for researchers at UNC to obtain both the plant material and specific cannabinoid reference standards needed to conduct the research.”

 

Now that’s impressive: We’ve watched many small MJ companies trying to put their stamp on the nation’s most explosive industry... but I’m unaware of ANY OTHER that has been granted federal permission for the use as a Class 1 substance.

 

As we touched on earlier, PMCB says they operate as a pure Biotech firm leveraging its Cell-in-a-Box technology.

 

This unique and patented technology will be used as a platform upon which treatments are being built for several types of cancer, including advanced inoperable pancreatic cancer, and diabetes.

 

PMCB is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.

 

In fact, just a couple months back, PMCB announced that the U.S. FDA has granted them Orphan Drug Designation for its pancreatic cancer treatment.

 

PMCB states that their treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or “cancer-killing” form. These capsules are placed as close to the tumor as possible to enable the delivery of the highest levels of the cancer-killing drug directly at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials.

 

In addition, PharmaCyte Biotech states they are developing treatments for cancer based upon chemical constituents of the Cannabis plant, known as cannabinoids.

 

As part of their research into cannabinoids, the Company has been examining ways to exploit the benefits of Cell-in-a-Box technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments.

 

PMCB plans to use this breakthrough technology to develop “Green” approaches to fighting deadly cancers, such as those of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide each year.

 

One thing of which this Company is particularly focused on is Diabetes. Type One and Two diabetes are both wreaking havoc across the world and in the U.S. alone more than 29.1Mln people are affected.

 

The markets for the treatments PMCB are working on are absolutely enormous.

 

    A report from Transparency Market Research states that the global market for biotechnology is projected to reach a value worth 414.5Bln Dlrs by the end of 2017.

    It is estimated that by 2017 the drugs treatment market for diabetes will be worth 55.3Bln Dlrs.

    The anti-diabetic medicines industry generated 35.6Bln Dlrs in 2012, and its revenues will show strong growth to 2023.

    Worldwide there are about 350Mln people who have been diagnosed with diabetes and countless Mln’s who remain undiagnosed. In the U.S. alone, the annual diabetes costs are approaching 300Bln Dlrs.

    In a recent poll from Gallup, in 2013 a record number of Americans were in favor of medical MJ (58%).

    Researchers found that more than 2.34Bln Dlrs of Med-MJ were to be sold in 2014.

    According to Greenwave Advisors, if all 50 states legalize MJ and the federal government followed suit, the combined sales for Medical and Recreational MJ would reach higher than 35Bln USD by 2020.

 

Right now biotech and cannabis are two of the hottest sectors and PMCB is in the thick of both.

 

Not only is this Company operating in the hottest markets out there, but have also made some enormous developments in recent months, which have placed them on the cutting-edge of these markets.

Wow!  I've never heard such a "high quality" sounding trade.  It seems like God has chosen me, I AM the CHOSEN ONE!  I cannot lose money on this trade!!  Woah woah woah...get ahold of yourself!  I know this sounds good, and we hardly ever hear about plays on the Discovery channel in 2 of the hottest industries on Earth.  But you must ignore all of that and put your CAUTIOUS TRADING RULES before anything else!  Also as I have said on previous relevant occasions...  Remember this is a play that has been falling hard.  In my personal opinion, all signs point to a MAJOR bounce, but if you see Thursday that PMCB surprises us and does NOT bounce...well, everyone knows what they say about catching a falling knife.

*** Be sure to trade with caution and to verify all information for yourself before trading.  Do your own research and consult with a licensed professional before trading any alert.  You may easily lose your entire investment.  In my personal opinion, the vast majority of companies alerted in this newsletter are too risky for traditional investment, and are discussed here purely from a short-term/daytrading perspective.  All traders should have substantial experience before engaging in the exceptionally risky process that is trading small, micro and nano-cap equities.  Watch out for morning gaps on evening alerts.  ***

 

Now let’s take a look at some of PMCB’s recent groundbreaking developments:

 

    Receiving “orphan drug” designation from the US FDA for the Company’s pancreatic cancer treatment, with applications filed with the EMA and the TGA for the same status in Europe and Australia.
    Development of a clinical protocol for a planned Phase 2b clinical trial with the goal of initiating the clinical trial in 2015.
    A preclinical study being completed evaluating the effectiveness of their pancreatic cancer treatment.
    The establishment of a worldwide Diabetes Consortium with a number of research agreements put into place with major universities and institutions that will permit the development of a breakthrough treatment for insulin dependent diabetes that combines Cell-in-a-Box with insulin-producing cells.
    Progression at the University of Northern Colorado in the pursuit of treatments for brain and other forms of difficult to treat cancer that will combine cannabinoid and related compounds with the Cell-in-a-Box technology.

 

"With exciting developments on the horizon for 2015, our work to develop treatments for both cancer and diabetes will move forward under our new name because it speaks to what we actually do here at PharmaCyte Biotech," concluded Mr. Waggoner, CEO of PharmaCyte Biotech.


 
 

PMCB stands a chance to continue making great leaps in 2015, and the recent developments have shown brilliant upside potential.

 

Also in the news of late was the Company’s announcement of success in the First Preclinical Test.

 

PMCB may have one of the most exclusive Biotech technologies that we’ve seen in the small markets for quite some time.

 

Also consider that PMCB is not only a biotech but that it is also developing MJ based treatments making it a part of the two hottest sectors on the small markets right now MJ and Biotech.

 

Currently at just around .10 there could be significant upside potential.

 

So get started on researching this exciting young pharma trade immediately… it could get very exciting very quickly.
 

PSA - Stock Psycho

www.pennystockalerts.com

Don’t ever invest based on the info or statements of this newsletter.  Do your own research and consult with a licensed professional before investing, only invest what you are prepared to lose. Any statements and opinions given are amateur and biased and should be treated as such. Past performance does not indicate future performance in any way. The performance of all alerts uncompensated and compensated in no way predict the performance of current and/or upcoming alerts. Check the latest SEC filings before investing, and research other information on the risks of investing in microcap companies at www.sec.gov


 

I would also like to explain to you in simple plain language, instead of overly complex and confusing "disclaimer language" many other newsletters use, exactly how I make money from operating this newsletter.

I am what is known as a STOCK PROMOTER!

That means I get paid to promote public companies.  An "alert" is really a promotion.  Check disclaimers and you will see this is the case at virtually all penny market newsletters.  Many of you assume I make money by getting paid in stock, or something of that nature.  This is not the case.  I make money by getting paid in cash, not stock.  Specifically, wire transfers in USD to my US based bank account.  This is the way most newsletters you read operate, and how they make money too. 

Sometimes I also have issued alerts where I get no payment and do not expect payment, and I just put out the alert at my own discretion.  Typically speaking, most alerts I issue are promotions for which I am paid.  You can always find this info in the disclaimer below.

Furthermore, while I always aggressively state the risks and dangers of trading my alerts, there is a danger that has recently come to my attention.  Various individuals in this "industry" have been accused of issuing press releases and/or general company info for various OTC companies that is false, fraudulent, exaggerated, and so on and so forth.  This means, even if you do very thorough due diligence on a stock, it is always possible that someone involved with the stock may have put false or exaggerated information out there that could be part of your research.  There are only a few cases that I am personally aware of, but how widespread this issue is, is unfortunately unknown.  You should keep this in mind when considering taking any trading action. This is further reason, in my personal opinion, why these OTC companies are not suitable for anything resembling a traditional investment.   (Long term gains are extremely rare)

Here is some information directly from the SEC Website: http://www.sec.gov/investor/pubs/cyberfraud/newsletter.htm

READ IMPORTANT DISCLAIMER

Disclaimer – This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by Focus Media.  Any reference to “we” or “our” refers to Focus Media.  Our business model is to be financially compensated to market and promote small public companies.  By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore unqualified to give investment recommendations. Always do your own research and consult with an licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
 
 
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on EOD or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices.
 

We have been compensated fifteen thousand dollars cash via bank deposit/wire to conduct a one day PMCB investor relations advertising campaign by a third party, Cream Consulting, which is currently active. Cream Consulting has also compensated us eleven thousand five hundred dollars for a prior one day PMCB campaign which has now expired, bringing our overall total compensation for PMCB to twenty six thousand five hundred dollars.  This compensation, both expired and currently active, is a major conflict of interest in our ability to be unbiased regarding PMCB. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Focus Media’s business model is to receive financial compensation to promote public companies.  Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forword looking statements, which are not guaranteed to materialize due to a variety of factors.

We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Focus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. See full disclaimer at www.pennystockalerts.com/disclaimer